Ignite Creation Date:
2024-05-06 @ 2:39 AM
Last Modification Date:
2024-10-26 @ 11:21 AM
Study NCT ID:
NCT02094573
Status:
COMPLETED
Last Update Posted:
2021-03-15
First Post:
2014-03-18
Brief Title:
A Study to Evaluate the Efficacy of Brigatinib AP26113 in Participants With Anaplastic Lymphoma Kinase ALK-Positive Non-small Cell Lung Cancer NSCLC Previously Treated With Crizotinib
Sponsor:
Ariad Pharmaceuticals
Organization:
Takeda
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-06-04
Start Date Type:
ACTUAL
Primary Completion Date:
2016-02-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-27
Completion Date Type:
ACTUAL
First Submit Date:
2014-03-18
First Submit QC Date:
March 21 2014
Study First Post Date:
2014-03-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2017-06-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-02-18
Last Update Post Date:
2021-03-15
Last Update Post Date Type:
ACTUAL